


Amendments to the Claims


1. (Currently amended) A compound represented by the formula (I)



wherein R¹ and R² are each optionally substituted ~~[[a]] lower alkyl-group optionally having substituents~~, or a salt thereof.

2. (Currently amended) The compound of claim 1, wherein R² is ~~[[a]] lower alkyl-group~~ substituted by an aromatic hydrocarbon-group, or a salt thereof.

3. (Currently amended) A compound represented by the formula (I)



wherein R¹ is optionally substituted ~~[[a]] lower alkyl-group optionally having substituents~~, R² is ~~[[a]] lower alkyl-group~~, or a salt thereof.

4. (Currently amended) The compound of claim 3, wherein R² is ~~[[a]] lower alkyl-group~~ having consisting of 3 or 4 carbon atoms, or a salt thereof.

5. (Currently amended) The compound of claim 4, wherein the lower alkyl-group is isopropyl or isobutyl, or a salt thereof.

6. (Currently amended) The compound of claim 1, wherein R¹ is ~~[[a]]~~ substituted lower alkyl-group ~~having substituent(s)~~, or a salt thereof.

7. (Currently amended) The compound of claim 6, wherein the ~~substituent(s) that the lower alkyl-group has~~ is substituted with an optionally substituted aromatic hydrocarbon-group ~~optionally having substituents~~, or a salt thereof.


8. (Currently amended) The compound of claim 7, wherein the optionally substituted aromatic hydrocarbon-group is an aromatic hydrocarbon-group substituted ~~by~~ with a-group substituent selected from the group consisting of a ~~hydroxy-group~~ hydroxyl, ~~[[a]] lower alkoxy group~~, ~~[[a]] cyclohexylmethoxy-group~~, ~~[[a]] halogen-atom~~ and ~~[[a]] phenyl-group~~.

9. (Currently amended) The compound of claim 7, wherein the optionally substituted aromatic hydrocarbon-group is ~~[[a]] phenyl-group~~ or 2-naphthyl-group.

10. (Original) (2S,5S)-5-Benzyl-6-hydroxy-2-(2-methylpropyl)-3-morpholinone.

11-13. (Cancelled)


14. (Currently amended) A pharmaceutical composition comprising a compound represented by the formula (I)



wherein R¹ and R² are each optionally substituted ~~[[a]] lower alkyl-group optionally having substituents~~, or a salt thereof and a pharmaceutically acceptable carrier.

15. (Cancelled)

16. (Currently amended) A method for treating a disease in which calpain is involved ~~cataract or retinal ischemic disorder~~, which comprises administering an effective amount of a compound represented by the formula (I)



wherein R¹ and R² are each optionally substituted ~~[[a]] lower alkyl-group optionally having substituents~~, or a salt thereof, to a mammal in need of the treatment.

17. (Cancelled)

18. (Currently amended) The compound of claim 3, wherein R¹ is ~~[[a]] substituted lower alkyl-group having substituent(s)~~, or a salt thereof.

19. (Currently amended) The compound of claim 18, wherein the ~~substituent(s) that the lower alkyl is substituted with group has~~ is an optionally substituted aromatic hydrocarbon-group ~~optionally having substituents~~, or a salt thereof.

20. (Currently amended) The compound of claim 19, wherein the optionally substituted aromatic hydrocarbon-group is an aromatic hydrocarbon-group substituted with ~~by a group substituent~~ selected from the group consisting of a ~~hydroxy-group~~ hydroxyl, ~~[[a]] lower alkoxy group~~, ~~[[a]] cyclohexylmethoxy-group~~, ~~[[a]] halogen-atom~~ and ~~[[a]] phenyl-group~~.

21. (Currently amended) The compound of claim-20 ~~19~~, wherein the optionally substituted aromatic hydrocarbon-group is ~~[[a]] phenyl-group~~ or 2-naphthyl-group.